Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B001 in locally advanced or metastatic epithelial tumors
NCT04603287Phase 1Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Apr 2020
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of izalontamab in Epithelial tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Apr 2020; status: active, not recruiting.
02
Drugs
izalontamab
03
Conditions
Epithelial tumor
Beyond the preview
Go deeper on NCT04603287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603287.